Details for New Drug Application (NDA): 211907
✉ Email this page to a colleague
NDA 211907 describes ROPIVACAINE HYDROCHLORIDE, which is a drug marketed by Amneal, Caplin, Eugia Pharma, Gland Pharma Ltd, Hikma, Hospira, Inforlife, Kindos, Mylan Labs Ltd, Navinta Llc, Rising, and Somerset Theraps Llc, and is included in fifteen NDAs. It is available from twelve suppliers. Additional details are available on the ROPIVACAINE HYDROCHLORIDE profile page.
The generic ingredient in ROPIVACAINE HYDROCHLORIDE is ropivacaine hydrochloride. There are thirteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ropivacaine hydrochloride profile page.
The generic ingredient in ROPIVACAINE HYDROCHLORIDE is ropivacaine hydrochloride. There are thirteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the ropivacaine hydrochloride profile page.
Summary for 211907
| Tradename: | ROPIVACAINE HYDROCHLORIDE |
| Applicant: | Hikma |
| Ingredient: | ropivacaine hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INJECTION | Strength | 200MG/100ML (2MG/ML) | ||||
| Approval Date: | Aug 15, 2024 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INJECTION | Strength | 400MG/200ML (2MG/ML) | ||||
| Approval Date: | Aug 15, 2024 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INJECTION | Strength | 500MG/100ML (5MG/ML) | ||||
| Approval Date: | Aug 15, 2024 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
